Manipulating adrenergic stress receptor signaling to enhance immunosuppression and prolong survival of vascularized composite tissue transplants. Issue 8 (22nd August 2022)

• Record Type: Journal Article
• Authors: Kim, Minhyung; Fisher, Daniel T.; Bogner, Paul N.; Sharma, Umesh; Yu, Han; Skitzki, Joseph J.; Repasky, Elizabeth A.
• Is Part Of: Clinical and translational medicine. Volume 12:Issue 8(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-08-22
• Subjects: immunosuppression -- stress signalling -- vascularized composite tissue allotransplantation -- β2‐adrenergic receptors; Clinical medicine -- Periodicals; Medicine, Experimental -- Periodicals; Medical innovations -- Periodicals; Molecular biology -- Periodicals; Pathology, Molecular -- Periodicals; 616.027
• DOI: 10.1002/ctm2.996
• Languages: English
• ISSNs: 2001-1326

Abstract

Abstract: Background: Vascularized composite tissue allotransplantation (VCA) to replace limbs or faces damaged beyond repair is now possible. The resulting clear benefit to quality of life is a compelling reason to attempt this complex procedure. Unfortunately, the high doses of immunosuppressive drugs required to protect this type of allograft result in significant morbidity and mortality giving rise to ethical concerns about performing this surgery in patients with non‐life‐threatening conditions. Here we tested whether we could suppress anti‐graft immune activity by using a safe β2 ‐adrenergic receptor (AR) agonist, terbutaline, to mimic the natural immune suppression generated by nervous system‐induced signalling through AR. Methods: A heterotopic hind limb transplantation model was used with C57BL/6 (H‐2b) as recipients and BALB/c (H‐2d) mice as donors. To test the modulation of the immune response, graft survival was investigated after daily intraperitoneal injection of β2 ‐AR agonist with and without tacrolimus. Analyses of immune compositions and quantification of pro‐inflammatory cytokines were performed to gauge functional immunomodulation. The contributions to allograft survival of β2 ‐AR signalling in donor and recipient tissue were investigated with β2 ‐AR −/− strains. Results: Treatment with the β2 ‐AR agonist delayed VCA rejection, even with a subtherapeutic dose of tacrolimus. β2 ‐AR agonist decreased T‐cell infiltration into the transplanted grafts and decreased memory T‐cell populations in recipient's circulation. In addition, decreased levels of inflammatory cytokines (IFN‐γ, IL‐6, TNF‐α, CXCL‐1/10 and CCL3/4/5/7) were detected following β2 ‐AR agonist treatment, and there was a decreased expression of ICAM‐1 and vascular cell adhesion molecule‐1 in donor stromal cells. Conclusions: β2 ‐AR agonist can be used safely to mimic the natural suppression of immune responses, which occurs during adrenergic stress‐signalling and thereby can be used in combination regimens to reduce the dose needed of toxic immunosuppressive drugs such as tacrolimus. This strategy can be further evaluated for feasibility in the clinic. Abstract : Enhancing immunosuppression by adrenergic receptor manipulation using a β2 ‐agonist enhances VCA graft survival without increasing toxicity.